{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 52,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide uses a structured table to segment the patient population based on treatment history and specific genetic mutations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/30",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Sources: Ou and Zhu Lung Cancer 2019; Kris et. al. JAMA 2014; Shaw and Engelman J Clin Onc 2013; Noé et. al. J Thor Onc 2019; Peters et. al. NEJM 2017; Shaw et. al. Lancet Onc 2017; Dagogo-Jack et. al. Clin Cancer Res 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3de0c68c-acb9-47bf-a10e-938b92584366",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.86,
        "x": 0.07,
        "y": 0.265
      },
      "kind": "table",
      "text": "Table showing Line of Therapy, Sub-population, Incidence, CNS Disease, and Standard of Care",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e58d9b0d-11e7-49e4-be1a-ae13bbb5257e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "title",
      "text": "Emerging Resistance Mutations and Increasing CNS Involvement Limit Utility of Approved Therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74605027-e593-4f4f-9753-f4e97e4ec0b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.11
      },
      "kind": "title",
      "text": "ALK-Positive NSCLC Market Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "facb0926-1ffb-4e5b-9d1b-4f9d14016c1b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "43e9f227-0636-4ef8-b36d-ca19a0b50a27",
      "evidence": "components include table/data",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "9a41f4a5-9653-4612-a4d3-a9280c13015a",
      "evidence": "Segments market by treatment history and mutation profile",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 29,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5bd43550-4e7b-49ae-9310-ece1e67e14d2",
      "evidence": "Slides 29-40 present preclinical and clinical trial results for NVL-655.",
      "position": 1,
      "objective": "How can Nuvalent's therapies address the needs of patients with specific cancer mutations?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}